- Home
- CHRS vs CRVO Comparison
CHRS vs CRVO Comparison
Compare CHRS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CRVO
- Stock Information
- Founded
- CHRS 2010
- CRVO 2001
- Country
- CHRS United States
- CRVO United States
- Employees
- CHRS N/A
- CRVO N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- CRVO Health Care
- Exchange
- CHRS Nasdaq
- CRVO Nasdaq
- Market Cap
- CHRS 94.0M
- CRVO 95.4M
- IPO Year
- CHRS 2014
- CRVO N/A
- Fundamental
- Price
- CHRS $0.91
- CRVO $13.58
- Analyst Decision
- CHRS Strong Buy
- CRVO Strong Buy
- Analyst Count
- CHRS 4
- CRVO 8
- Target Price
- CHRS $5.38
- CRVO $25.43
- AVG Volume (30 Days)
- CHRS 2.1M
- CRVO 13.9M
- Earning Date
- CHRS 05-08-2025
- CRVO 05-13-2025
- Dividend Yield
- CHRS N/A
- CRVO N/A
- EPS Growth
- CHRS N/A
- CRVO N/A
- EPS
- CHRS 0.25
- CRVO N/A
- Revenue
- CHRS $266,959,999.00
- CRVO $9,737,974.00
- Revenue This Year
- CHRS N/A
- CRVO N/A
- Revenue Next Year
- CHRS $9.02
- CRVO N/A
- P/E Ratio
- CHRS $3.66
- CRVO N/A
- Revenue Growth
- CHRS 3.78
- CRVO 36.29
- 52 Week Low
- CHRS $0.66
- CRVO $1.80
- 52 Week High
- CHRS $2.61
- CRVO $25.92
- Technical
- Relative Strength Index (RSI)
- CHRS 45.16
- CRVO 70.67
- Support Level
- CHRS $0.89
- CRVO $8.64
- Resistance Level
- CHRS $1.07
- CRVO $10.72
- Average True Range (ATR)
- CHRS 0.09
- CRVO 2.51
- MACD
- CHRS -0.00
- CRVO 0.18
- Stochastic Oscillator
- CHRS 44.79
- CRVO 70.88
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.